Gapping up
In reaction to strong earnings/guidance: AKS +0.9%, (provides Q2 guidance)
M&A news: STRN +62.1% (to be acquired by an affiliate of Hach Company for $8.50/share, or ~$39 mln), WMB +28.6% (Energy Transfer Equity (ETE) confirms proposal to merge with The Williams Companies (WMB)), CNIT +17.6% (receives a preliminary non-binding 'going private' proposal for $4.43/share), CI +8.7% (Anthem (ANTM) offers to acquire Cigna for $184 per share; CI rejected bid), VIMC +4.2% (receives offer from Co-CEO's to acquire the co for $13.50 per ADS), AMD +2.7% (considering options including possible breakup or spinoff, according to Reuters; Extreme Tech report suggests AMD denied speculation that it is considering a breakup), HUM +2.3% (Aetna (AET) has offered to purchase HUM for an unknown amount, according to WSJ), AET +2.2%
Select EU related names showing strength with DAX ~+3% this morning: SAN +3.7%, ING +3.6%, DB +3.5%, NVO +3.5%, SNY +3%, SAP +2.6%, ASML +2.4%, VOD +2%, PHG +2%, UN +1.8%
Select oil/gas related names showing strength: TOT +2.6%, NGLS +2.6%, ETP +1.6%, RIG +1.1%
Other news: TBIO +15.8% (to launch up to six new genetic cancer tests this year, based on its Multiplexed ICE COLD-PCR technology ), EPZM +15.7% (reports positive data from ongoing Phase 1 study of Tazemetostat), NBG +8.2% (optimism coming out of Greece to finalize deal today), NVIV +7.8% (announces it has received a notice of allowance from the USPTO stating that a patent application has cleared internal review and is pending issuance), ANTH +7.4% (added to Russell 3K), KTOS +5.4% (favorable commentary on Friday's Mad Money), KMDA +5.4% (enters into a collaboration with Baxalta International (BXLT) for a phase 1/2 clinical trial of Kamada's alpha-1 antitrypsin), GDP +4.4% (says that it has commenced completion operations on two of its six drilled but uncompleted wells in the Tuscaloosa Marine Shale; Reaffirms Q2 CapEx), KITE +4.3% (Kite Pharma and Bluebird Bio (BLUE) to collaborate to co-develop/commercialize second generation T cell receptor product candidates directed against HPV associated cancers), TEDU +3.9% (announces stock purchase agreement with KKR and Founder Shaoyun Han, for $90.5 mln in common shares), HNSN +2.8% (files to sell ~177.83 mln shares on behalf of selling shareholders), POZN +2% (announces executive changes, Mark A. Glickman named Chief Commercial Officer), ALU +1.9% (announced that the brand will be the Official Smartphone Partner of Toronto FC),MNKD +1.5% (still checking), RCL +1.4% (discloses entry into an agreement to amend and restate its current $1.1 bln unsecured revolving credit facility)
Analyst comments: ONCS +5.5% (assumed with a Buy at H.C. Wainwright; $25 tgt), RXDX +5.2% (initiated with a Overweight at Piper Jaffray), BLRX +4.3% (initiated with a Mkt Outperform at JMP Securities), SFUN +3.8% (initiated with an Overweight at Barclays), STM +3.8% (upgraded to Equal Weight from Underweight at Barclays), CCL +3.2% (upgraded to Buy from Hold at Deutsche Bank), CNHI +3% (upgraded to Neutral from Underweight at JP Morgan), NVMI +1.9% (upgraded to Buy from Hold at Canaccord Genuity), FB +1.7% (target raised to $120 from $92 at Piper Jaffray), EXPE +1.6% (upgraded to Buy at Deutsche Bank), NVS +1.4% (upgraded to Buy at Bryan Garnier), NFLX +1.2% (target raised to $950 from $600 at BTIG Research), AGCO +1.1% (upgraded to Neutral from Underweight at JP Morgan), EMN +1.1% (upgraded to Buy from Neutral at Nomura), PPL +1% (upgraded to Buy from Hold at Jefferies), CAG +1% (upgraded to Overweight from Neutral at JP Morgan), HSBC +0.8% (upgraded to Buy at Investec
)
In reaction to strong earnings/guidance: AKS +0.9%, (provides Q2 guidance)
M&A news: STRN +62.1% (to be acquired by an affiliate of Hach Company for $8.50/share, or ~$39 mln), WMB +28.6% (Energy Transfer Equity (ETE) confirms proposal to merge with The Williams Companies (WMB)), CNIT +17.6% (receives a preliminary non-binding 'going private' proposal for $4.43/share), CI +8.7% (Anthem (ANTM) offers to acquire Cigna for $184 per share; CI rejected bid), VIMC +4.2% (receives offer from Co-CEO's to acquire the co for $13.50 per ADS), AMD +2.7% (considering options including possible breakup or spinoff, according to Reuters; Extreme Tech report suggests AMD denied speculation that it is considering a breakup), HUM +2.3% (Aetna (AET) has offered to purchase HUM for an unknown amount, according to WSJ), AET +2.2%
Select EU related names showing strength with DAX ~+3% this morning: SAN +3.7%, ING +3.6%, DB +3.5%, NVO +3.5%, SNY +3%, SAP +2.6%, ASML +2.4%, VOD +2%, PHG +2%, UN +1.8%
Select oil/gas related names showing strength: TOT +2.6%, NGLS +2.6%, ETP +1.6%, RIG +1.1%
Other news: TBIO +15.8% (to launch up to six new genetic cancer tests this year, based on its Multiplexed ICE COLD-PCR technology ), EPZM +15.7% (reports positive data from ongoing Phase 1 study of Tazemetostat), NBG +8.2% (optimism coming out of Greece to finalize deal today), NVIV +7.8% (announces it has received a notice of allowance from the USPTO stating that a patent application has cleared internal review and is pending issuance), ANTH +7.4% (added to Russell 3K), KTOS +5.4% (favorable commentary on Friday's Mad Money), KMDA +5.4% (enters into a collaboration with Baxalta International (BXLT) for a phase 1/2 clinical trial of Kamada's alpha-1 antitrypsin), GDP +4.4% (says that it has commenced completion operations on two of its six drilled but uncompleted wells in the Tuscaloosa Marine Shale; Reaffirms Q2 CapEx), KITE +4.3% (Kite Pharma and Bluebird Bio (BLUE) to collaborate to co-develop/commercialize second generation T cell receptor product candidates directed against HPV associated cancers), TEDU +3.9% (announces stock purchase agreement with KKR and Founder Shaoyun Han, for $90.5 mln in common shares), HNSN +2.8% (files to sell ~177.83 mln shares on behalf of selling shareholders), POZN +2% (announces executive changes, Mark A. Glickman named Chief Commercial Officer), ALU +1.9% (announced that the brand will be the Official Smartphone Partner of Toronto FC),MNKD +1.5% (still checking), RCL +1.4% (discloses entry into an agreement to amend and restate its current $1.1 bln unsecured revolving credit facility)
Analyst comments: ONCS +5.5% (assumed with a Buy at H.C. Wainwright; $25 tgt), RXDX +5.2% (initiated with a Overweight at Piper Jaffray), BLRX +4.3% (initiated with a Mkt Outperform at JMP Securities), SFUN +3.8% (initiated with an Overweight at Barclays), STM +3.8% (upgraded to Equal Weight from Underweight at Barclays), CCL +3.2% (upgraded to Buy from Hold at Deutsche Bank), CNHI +3% (upgraded to Neutral from Underweight at JP Morgan), NVMI +1.9% (upgraded to Buy from Hold at Canaccord Genuity), FB +1.7% (target raised to $120 from $92 at Piper Jaffray), EXPE +1.6% (upgraded to Buy at Deutsche Bank), NVS +1.4% (upgraded to Buy at Bryan Garnier), NFLX +1.2% (target raised to $950 from $600 at BTIG Research), AGCO +1.1% (upgraded to Neutral from Underweight at JP Morgan), EMN +1.1% (upgraded to Buy from Neutral at Nomura), PPL +1% (upgraded to Buy from Hold at Jefferies), CAG +1% (upgraded to Overweight from Neutral at JP Morgan), HSBC +0.8% (upgraded to Buy at Investec
)